Confo Therapeutics, a Ghent, Belgium-based clinical-stage firm and innovator within the discovery of medicines concentrating on G-protein coupled receptors (GPCRs), raised EUR60M in Collection B funding.
The spherical was led by Ackermans & van Haaren (AvH) and included participation from further new traders, Driehaus Capital Administration and Quest for Development (QfG), in addition to present traders, BioGeneration Ventures (BGV), Capricorn Well being-tech Fund (CHF), Fund+, MINTS (College of Michigan), Perceptive Advisors, Qbic, PMV, V-Bio Ventures, VIB and Wellington Companions. As a part of the Collection B financing spherical, Dr. Vangindertael will be a part of Confo’s Board of Administrators, and Mr. Alex Munns, Assistant Portfolio Supervisor at Driehaus, will probably be appointed as Board Observer.
The corporate intends to make use of the funds to advance two, wholly owned packages by Part 1 and two further packages to IND approval, together with molecules concentrating on GPR75 for weight problems.
Led by CEO Cedric Ververken, Confo Therapeutics is a clinical-stage biotechnology firm dedicated to figuring out and accelerating novel medicines concentrating on GPCRs (G protein-coupled receptors). It discovers small molecules and antibodies with the specified pharmacology by using its proprietary discovery platform which makes use of conformation-specific ConfoBodies® to advertise GPCRs into functionally related states.
FinSMEs
26/07/2024
